{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T05:40:02Z","timestamp":1739079602606,"version":"3.37.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea","award":["A080553"],"award-info":[{"award-number":["A080553"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of novel therapies for chronic hepatitis C by modulating innate and adaptive immune responses are reviewed.<\/jats:p><jats:p>Chronic, persistent HCV infection is a public health issue. It often progresses to life-threatening complications, including liver cirrhosis and hepatocellular carcinoma. The current standard therapy is a combination of pegylated IFN-\u03b1 and ribavirin. This therapy results in a sustained virologic response in only 50% of patients infected with HCV genotype 1 and is often accompanied with substantial side-effects. Therefore, it is imperative to develop novel therapies with higher efficacy and less substantial side-effects. Impaired immune responses to HCV are key features of chronic HCV infection; thus, intervention strategies typically involve boosting the immune responses against HCV. These immune-based therapies for chronic HCV infection include therapeutic vaccines, antagonists of T cell inhibitory factors, anti-HCV neutralizing antibodies, cytokines, and agonists for TLRs. Currently, various types of immune-based therapies are under development that might be used as a monotherapy or in combination with other antiviral drugs for the treatment of chronic HCV infection.<\/jats:p>","DOI":"10.1189\/jlb.1208772","type":"journal-article","created":{"date-parts":[[2009,4,25]],"date-time":"2009-04-25T00:44:21Z","timestamp":1240620261000},"page":"33-39","source":"Crossref","is-referenced-by-count":6,"title":["Immune-based therapy for chronic hepatitis C"],"prefix":"10.1093","volume":"86","author":[{"given":"Dong-Yeop","family":"Chang","sequence":"first","affiliation":[{"name":"Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering , KAIST, Daejeon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering , KAIST, Daejeon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"2023032919210594900_jlb0033-cit-b1","first-page":"341","article-title":"HCV: global prevention","volume":"72","author":"World Health Organization","year":"1997","journal-title":"Wkly. Epidemiol. Rec."},{"key":"2023032919210594900_jlb0033-cit-b2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"2023032919210594900_jlb0033-cit-b3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon \u03b1-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2023032919210594900_jlb0033-cit-b4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon \u03b1-2b plus ribavirin compared with interferon \u03b1-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"2023032919210594900_jlb0033-cit-b5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"2023032919210594900_jlb0033-cit-b7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.immunol.25.022106.141602","article-title":"Flying under the radar: the immunobiology of hepatitis C","volume":"25","author":"Dustin","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"2023032919210594900_jlb0033-cit-b8","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI29832","article-title":"Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection","volume":"116","author":"Shin","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2023032919210594900_jlb0033-cit-b9","doi-asserted-by":"crossref","first-page":"9782","DOI":"10.1128\/JVI.00475-08","article-title":"The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection","volume":"82","author":"Shin","year":"2008","journal-title":"J. Virol."},{"key":"2023032919210594900_jlb0033-cit-b10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"2023032919210594900_jlb0033-cit-b11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1053\/j.gastro.2008.02.058","article-title":"Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41","volume":"134","author":"Klade","year":"2008","journal-title":"Gastroenterology"},{"key":"2023032919210594900_jlb0033-cit-b12","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2007.06.026","article-title":"Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients","volume":"25","author":"Schlaphoff","year":"2007","journal-title":"Vaccine"},{"key":"2023032919210594900_jlb0033-cit-b13","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1016\/j.vaccine.2007.08.005","article-title":"Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy","volume":"25","author":"Yutani","year":"2007","journal-title":"Vaccine"},{"key":"2023032919210594900_jlb0033-cit-b14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/jhep.2003.50474","article-title":"A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C","volume":"38","author":"Nevens","year":"2003","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"2023032919210594900_jlb0033-cit-b16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jhep.2007.04.018","article-title":"Randomized placebo controlled phase I\/II trial of \u03b1-galactosylceramide for the treatment of chronic hepatitis C","volume":"47","author":"Veldt","year":"2007","journal-title":"J. Hepatol."},{"key":"2023032919210594900_jlb0033-cit-b17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm0306-276","article-title":"Taking the brake off T cells in chronic viral infection","volume":"12","author":"Shin","year":"2006","journal-title":"Nat. Med."},{"key":"2023032919210594900_jlb0033-cit-b18","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"2023032919210594900_jlb0033-cit-b19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"2023032919210594900_jlb0033-cit-b20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"2023032919210594900_jlb0033-cit-b21","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.01177-06","article-title":"PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion","volume":"80","author":"Urbani","year":"2006","journal-title":"J. Virol."},{"key":"2023032919210594900_jlb0033-cit-b22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/JVI.02021-06","article-title":"Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression","volume":"81","author":"Radziewicz","year":"2007","journal-title":"J. Virol."},{"key":"2023032919210594900_jlb0033-cit-b23","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1128\/JVI.00409-07","article-title":"Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction","volume":"81","author":"Golden-Mason","year":"2007","journal-title":"J. Virol."},{"key":"2023032919210594900_jlb0033-cit-b24","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1053\/j.gastro.2008.02.033","article-title":"Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization","volume":"134","author":"Nakamoto","year":"2008","journal-title":"Gastroenterology"},{"key":"2023032919210594900_jlb0033-cit-b25","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.4049\/jimmunol.181.12.8215","article-title":"High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection","volume":"181","author":"Rutebemberwa","year":"2008","journal-title":"J. Immunol."},{"key":"2023032919210594900_jlb0033-cit-b26","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1084\/jem.20061462","article-title":"Resolution of a chronic viral infection after interleukin-10 receptor blockade","volume":"203","author":"Ejrnaes","year":"2006","journal-title":"J. Exp. Med."},{"key":"2023032919210594900_jlb0033-cit-b27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","article-title":"Interleukin-10 determines viral clearance or persistence in vivo","volume":"12","author":"Brooks","year":"2006","journal-title":"Nat. Med."},{"key":"2023032919210594900_jlb0033-cit-b28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2008.03.016","article-title":"Therapeutic vaccination for hepatitis C: can protective T-cell responses be restored after prolonged antigen exposure?","volume":"134","author":"Ferrari","year":"2008","journal-title":"Gastroenterology"},{"key":"2023032919210594900_jlb0033-cit-b29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1084\/jem.20071949","article-title":"Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection","volume":"205","author":"Ha","year":"2008","journal-title":"J. Exp. Med."},{"key":"2023032919210594900_jlb0033-cit-b30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.20071948","article-title":"IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection","volume":"205","author":"Brooks","year":"2008","journal-title":"J. Exp. Med."},{"key":"2023032919210594900_jlb0033-cit-b31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"2023032919210594900_jlb0033-cit-b32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jhep.2006.08.019","article-title":"Clinical evaluation (phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity","volume":"46","author":"Galun","year":"2007","journal-title":"J. Hepatol."},{"key":"2023032919210594900_jlb0033-cit-b33","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver Transpl."},{"key":"2023032919210594900_jlb0033-cit-b34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/lt.20405","article-title":"A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl."},{"key":"2023032919210594900_jlb0033-cit-b35","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1053\/j.gastro.2008.05.020","article-title":"Broadly neutralizing antibodies against hepatitis C virus: new hope for immunization?","volume":"134","author":"Abu Dayyeh","year":"2008","journal-title":"Gastroenterology"},{"key":"2023032919210594900_jlb0033-cit-b36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"2023032919210594900_jlb0033-cit-b37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1053\/jhep.2002.31770","article-title":"Interferon-\u03b3 inhibits replication of subgenomic and genomic hepatitis C virus RNAs","volume":"35","author":"Frese","year":"2002","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b38","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.1128\/JVI.76.21.11148-11154.2002","article-title":"Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by \u03b1, \u03b2, and \u03b3 interferons","volume":"76","author":"Cheney","year":"2002","journal-title":"J. Virol."},{"key":"2023032919210594900_jlb0033-cit-b39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2005.02.023","article-title":"Pilot study of interferon \u03b3 for chronic hepatitis C","volume":"43","author":"Soza","year":"2005","journal-title":"J. Hepatol."},{"key":"2023032919210594900_jlb0033-cit-b40","doi-asserted-by":"crossref","first-page":"13412","DOI":"10.1128\/JVI.79.21.13412-13420.2005","article-title":"Liver-directed \u03b3 interferon gene delivery in chronic hepatitis C","volume":"79","author":"Shin","year":"2005","journal-title":"J. Virol."},{"key":"2023032919210594900_jlb0033-cit-b41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/hep.510290429","article-title":"A phase I\/II study of recombinant human interleukin-12 in patients with chronic hepatitis C","volume":"29","author":"Zeuzem","year":"1999","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b42","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0002-9270(01)02520-5","article-title":"A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-\u03b1","volume":"96","author":"O'Brien","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"2023032919210594900_jlb0033-cit-b43","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/jhep.2003.50242","article-title":"A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy","volume":"37","author":"Pockros","year":"2003","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ni1303","article-title":"Innate immune recognition of viral infection","volume":"7","author":"Kawai","year":"2006","journal-title":"Nat. Immunol."},{"key":"2023032919210594900_jlb0033-cit-b45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.20839","article-title":"Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection","volume":"42","author":"Horsmans","year":"2005","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2007.02.025","article-title":"Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies","volume":"47","author":"Pockros","year":"2007","journal-title":"J. Hepatol."},{"key":"2023032919210594900_jlb0033-cit-b47","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1073\/pnas.0510801103","article-title":"Activation of anti-hepatitis C virus responses via Toll-like receptor 7","volume":"103","author":"Lee","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023032919210594900_jlb0033-cit-b48","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.21773","article-title":"Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus","volume":"46","author":"McHutchison","year":"2007","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nat. Med."},{"key":"2023032919210594900_jlb0033-cit-b50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.tibtech.2004.08.011","article-title":"Biomedicines to reduce inflammation but not viral load in chronic HCV\u2014what's the sense?","volume":"22","author":"Chuang","year":"2004","journal-title":"Trends Biotechnol."},{"key":"2023032919210594900_jlb0033-cit-b51","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.vaccine.2008.03.021","article-title":"Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C","volume":"26","author":"Batdelger","year":"2008","journal-title":"Vaccine"},{"key":"2023032919210594900_jlb0033-cit-b52","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1096\/fj.00-0908fje","article-title":"Tumor necrosis factor \u03b1 attenuates interferon \u03b1 signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy","volume":"15","author":"Hong","year":"2001","journal-title":"FASEB J."},{"key":"2023032919210594900_jlb0033-cit-b53","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1099\/vir.0.18997-0","article-title":"Hepatitis C virus RNA replication is resistant to tumor necrosis factor-\u03b1","volume":"84","author":"Frese","year":"2003","journal-title":"J. Gen. Virol."},{"key":"2023032919210594900_jlb0033-cit-b54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J. Hepatol."},{"key":"2023032919210594900_jlb0033-cit-b55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0016-5085(00)70134-X","article-title":"Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders","volume":"118","author":"Nelson","year":"2000","journal-title":"Gastroenterology"},{"key":"2023032919210594900_jlb0033-cit-b56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/hep.1840380412","article-title":"Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect","volume":"38","author":"Nelson","year":"2003","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b57","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/17826","article-title":"Inhibition of transforming growth factor-\u03b2\/SMAD signaling by the interferon-\u03b3\/STAT pathway","volume":"397","author":"Ulloa","year":"1999","journal-title":"Nature"},{"key":"2023032919210594900_jlb0033-cit-b58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hep.21561","article-title":"Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-\u03b31b in chronic hepatitis C patients with advanced fibrosis or cirrhosis","volume":"45","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hep.1840130220","article-title":"High doses of recombinant \u03b1-interferon or \u03b3-interferon for chronic hepatitis C: a randomized, controlled trial","volume":"13","author":"S\u00e1ez-Royuela","year":"1991","journal-title":"Hepatology"},{"key":"2023032919210594900_jlb0033-cit-b60","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2023032919210594900_jlb0033-cit-b61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1189%2Fjlb.1208772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/86\/1\/33\/49606813\/jlb0033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/86\/1\/33\/49606813\/jlb0033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T05:01:23Z","timestamp":1739077283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/86\/1\/33\/6959589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,4,24]]},"published-print":{"date-parts":[[2009,4,24]]}},"URL":"https:\/\/doi.org\/10.1189\/jlb.1208772","relation":{},"ISSN":["1938-3673","0741-5400"],"issn-type":[{"type":"electronic","value":"1938-3673"},{"type":"print","value":"0741-5400"}],"subject":[],"published-other":{"date-parts":[[2009,7]]},"published":{"date-parts":[[2009,4,24]]}}}